HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

First-Ever Rapid-Result Hematology Analyzer Measures Disease and Infection at POC

By HospiMedica International staff writers
Posted on 31 Mar 2023
Print article
Image: QScout RLD reports white blood cell count and differential from a drop of blood at patient-side in two minutes (Photo courtesy of Ad Astra)
Image: QScout RLD reports white blood cell count and differential from a drop of blood at patient-side in two minutes (Photo courtesy of Ad Astra)

Sepsis is a severe medical emergency that occurs when the body reacts strongly to an infection. This life-threatening condition is triggered by a chain reaction throughout the body, often starting from infections in the lung, urinary tract, skin, or gastrointestinal tract. Nearly any infection can lead to sepsis, which occurs when a localized infection progresses to severe infection throughout the body. According to a 2020 study, sepsis caused almost 11 million deaths worldwide in 2017, accounting for nearly 20% of all deaths in that year. Now, a new rapid-result hematology system comes with the capability to count immature infection-fighting granulocytes, one of the earliest markers for sepsis.

The QScout RLD rapid-result hematology system from Ad Astra Diagnostics, Inc. (AAD, Morrisville, NC, USA) is designed to measure white blood cell count, neutrophil-to-lymphocyte ratio, and counts of six white blood cell types in fingerstick or venous blood. QScout is the first hematology platform designed to quickly and accurately measure disease and infection, including a ratio of two white blood cell types (neutrophil-to-lymphocyte ratio) and count of immature granulocytes, at the point of care.

The QScout system uses a Rapid Leukocyte Differential (RLD) test that contains a dried reagent to stain cells. Whole blood is added to the test and inserted into the QScout Lab analyzer. The analyzer's optical system captures images of the cells, while an algorithm quickly identifies them, and results are displayed within two minutes. Ad Astra has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the QScout RLD. The company aims to expedite the regulatory review process to obtain clearance for the system's use at the point of care, where faster results can improve health outcomes, and in the lab, where it can enhance efficiency.

“QScout RLD was designed as a quick, quantitative 'scout' for infection that is simple enough to operate yet robust enough to deliver reliable data patient-side,” said AAD's chief scientific officer and co-founder, Rudy Rodriguez. “In doing so, QScout RLD offers the potential to democratize access to quality diagnostics, while providing healthcare professionals with a potentially life-saving tool.”

Related Links:
Ad Astra Diagnostics 

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Compact C-Arm
Arcovis DRF-C S21

Print article

Channels

Critical Care

view channel
Image: The new risk assessment tool determines patient-specific risks of developing unfavorable outcomes with heart failure (Photo courtesy of 123RF)

Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients

Heart failure is a serious condition where the heart cannot pump sufficient blood to meet the body's needs, leading to symptoms like fatigue, weakness, and swelling in the legs and feet, and it can ultimately... Read more

Surgical Techniques

view channel
Image: The multi-sensing device can be implanted into blood vessels to help physicians deliver timely treatment (Photo courtesy of IIT)

Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health

Researchers have embarked on a project to develop a multi-sensing device that can be implanted into blood vessels like peripheral veins or arteries to monitor a range of bodily parameters and overall health status.... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more